sur Biophytis (EPA:ALBPS)
Biophytis Expands AI Partnership with LynxKite for Longevity Drug Discovery
Biophytis, a biotech company in Paris, has announced an expansion of its alliance with LynxKite Technologies. This collaboration focuses on AI-driven drug discovery targeting age-related diseases. A notable project, MASSIVE, aims to identify Mas receptor activator drugs for sarcopenia, a muscle disease linked to aging.
The partnership combines Biophytis' expertise in Mas receptor pharmacology with LynxKite's AI technologies. This alliance supports Singapore's RIE 2030 plan, aligning with global efforts to address diseases affecting the elderly. LynxKite's platform integrates NVIDIA tools and cloud services, enhancing computational methods for longevity research.
Key goals include modeling drug structures using AI, generating synthetic candidates, and testing Mas receptor activators. This collaboration underlines Biophytis' commitment to innovative therapies, further reinforcing its drug discovery platform for longevity therapeutics.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biophytis